30.90
price down icon0.23%   -0.07
after-market アフターアワーズ: 30.90
loading

Genmab Adr (GMAB) 最新ニュース

pulisher
Feb 06, 2026

Genmab A/S (NASDAQ:GMAB): A GARP Case Study in Affordable Biotech Growth - Chartmill

Feb 06, 2026
pulisher
Feb 03, 2026

Targeted Cancer Therapy Market to Reach US$ 175.48 Billion by 2035 Driven by Precision Oncology Adoption, ADC Innovation, and Regulatory Productivity Says Astute Analytica - GlobeNewswire Inc.

Feb 03, 2026
pulisher
Feb 01, 2026

Federated Hermes Inc. Makes New Investment in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Feb 01, 2026
pulisher
Jan 31, 2026

What is HC Wainwright’s Estimate for Genmab A/S Q4 Earnings? - Defense World

Jan 31, 2026
pulisher
Jan 30, 2026

What is HC Wainwright's Estimate for Genmab A/S Q4 Earnings? - MarketBeat

Jan 30, 2026
pulisher
Jan 29, 2026

HC Wainwright Boosts Earnings Estimates for Genmab A/S - MarketBeat

Jan 29, 2026
pulisher
Jan 29, 2026

GENMAB A/S (NASDAQ:GMAB) Stands Out as a Peter Lynch-Style GARP Investment - Chartmill

Jan 29, 2026
pulisher
Jan 29, 2026

Stocks Showing Rising Market Leadership: BeOne Medicines ADR Earns 84 RS Rating - Investor's Business Daily

Jan 29, 2026
pulisher
Jan 28, 2026

Genmab A/S (NASDAQ:GMAB) Shares Gap DownHere's What Happened - MarketBeat

Jan 28, 2026
pulisher
Jan 26, 2026

GENMAB A/S -SP ADR (NASDAQ:GMAB) Combines Strong Growth with Bullish Technical Formation - Chartmill

Jan 26, 2026
pulisher
Jan 24, 2026

GENMAB A/S (NASDAQ:GMAB) Presents a Compelling Blend of Strong Fundamentals and Bullish Technicals - Chartmill

Jan 24, 2026
pulisher
Jan 24, 2026

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Jan 24, 2026
pulisher
Jan 24, 2026

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Jan 24, 2026
pulisher
Jan 20, 2026

Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside - Finviz

Jan 20, 2026
pulisher
Jan 16, 2026

Ascendis Pharma ADR shows rising price performance with jump to 83 RS rating - MSN

Jan 16, 2026
pulisher
Jan 15, 2026

Genmab A/S (GMAB): A Bull Case Theory - Finviz

Jan 15, 2026
pulisher
Jan 15, 2026

Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 - Investor's Business Daily

Jan 15, 2026
pulisher
Jan 15, 2026

Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily

Jan 15, 2026
pulisher
Jan 15, 2026

Eagle Global Advisors LLC Buys 34,175 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat

Jan 15, 2026
pulisher
Jan 15, 2026

Genmab ADR Joins Rank Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Jan 15, 2026
pulisher
Jan 14, 2026

Genmab A/S (NASDAQ:GMAB) Hits New 52-Week HighTime to Buy? - MarketBeat

Jan 14, 2026
pulisher
Jan 14, 2026

Genmab A/S (OTCMKTS:GNMSF) Reaches New 1-Year HighShould You Buy? - MarketBeat

Jan 14, 2026
pulisher
Jan 13, 2026

Moderna Stock Gets Healthy Relative Strength Rating Jump - Investor's Business Daily

Jan 13, 2026
pulisher
Jan 13, 2026

Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - MSN

Jan 13, 2026
pulisher
Jan 11, 2026

Quoin Pharm ADR clears technical benchmark, hitting 90-plus RS rating - MSN

Jan 11, 2026
pulisher
Jan 08, 2026

Genmab A/SAmerican Depositary Shares (NQ: GMAB - FinancialContent

Jan 08, 2026
pulisher
Jan 07, 2026

Genmab A/S (OTCMKTS:GNMSF) Reaches New 52-Week HighHere's What Happened - MarketBeat

Jan 07, 2026
pulisher
Jan 07, 2026

Stocks To Watch: Immunocore Holdings ADR Sees RS Rating Rise To 83 - MSN

Jan 07, 2026
pulisher
Jan 02, 2026

Genmab A/S (NASDAQ:GMAB) Shares Down 3.5% – Here’s Why - Defense World

Jan 02, 2026
pulisher
Dec 31, 2025

Genmab A/S (NASDAQ:GMAB) Stock Price Down 3.5%Time to Sell? - MarketBeat

Dec 31, 2025
pulisher
Dec 31, 2025

Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus - TechStock²

Dec 31, 2025
pulisher
Dec 30, 2025

Ascendis Pharma ADR reaches 80-plus relative strength rating benchmark - MSN

Dec 30, 2025
pulisher
Dec 30, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 30, 2025
pulisher
Dec 30, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Dec 30, 2025
pulisher
Dec 29, 2025

Genmab Portfolio Prioritization Update - GlobeNewswire

Dec 29, 2025
pulisher
Dec 28, 2025

Genmab–BioNTech cancer antibody trial ends early: What investors need to know - MSN

Dec 28, 2025
pulisher
Dec 26, 2025

Genmab–BioNTech Cancer Antibody Trial Ends Early: What Investors Need to Know - TipRanks

Dec 26, 2025
pulisher
Dec 23, 2025

Genmab A/S (NASDAQ:GMAB) Reaches New 1-Year HighStill a Buy? - MarketBeat

Dec 23, 2025
pulisher
Dec 19, 2025

Squarepoint Ops LLC Has $1.95 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Dec 19, 2025
pulisher
Dec 16, 2025

China Universal Asset Management Co. Ltd. Has $381,000 Stake in Genmab A/S Sponsored ADR $GMAB - Defense World

Dec 16, 2025
pulisher
Dec 16, 2025

The 5 Best Stocks To Buy And Watch Right Now - Investor's Business Daily

Dec 16, 2025
pulisher
Dec 11, 2025

Pipeline of Proprietary Antibodies - flow – Deutsche Bank

Dec 11, 2025
pulisher
Dec 11, 2025

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 86,842 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat

Dec 11, 2025
pulisher
Dec 10, 2025

Genmab A/S Sponsored ADR $GMAB Shares Bought by First Trust Advisors LP - Defense World

Dec 10, 2025
pulisher
Dec 09, 2025

Quoin Pharm ADR Joins Rank Of Stocks With RS Ratings Over 90 - MSN

Dec 09, 2025
pulisher
Dec 09, 2025

Dow Jones Stock Caterpillar In Buy Zone After Recent Breakout Move - Investor's Business Daily

Dec 09, 2025
pulisher
Dec 08, 2025

Marshall Wace LLP Cuts Stock Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat

Dec 08, 2025
pulisher
Dec 07, 2025

Genmab A/S Sponsored ADR $GMAB Shares Sold by American Century Companies Inc. - Defense World

Dec 07, 2025
$44.65
price up icon 1.25%
$108.39
price up icon 5.48%
$106.62
price up icon 1.02%
$149.86
price down icon 0.77%
biotechnology ONC
$353.92
price up icon 1.99%
大文字化:     |  ボリューム (24 時間):